OverviewSuggest Edit

Surmodics provides medical devices and in vitro diagnostic technologies to the healthcare industry. The Company offers surface modification and drug delivery coating technologies, as well as provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers. It also manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, and surface coatings to the diagnostic, biomedical research, and life science markets.

TypePublic
Founded1979
HQEden Prairie, US
Websitesurmodics.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Nov 2019)369(+10%)
Job Openings10
Revenue (FY, 2019)$100.1 M(+24%)
Share Price (Jan 2020)$41.1

SurModics Office Locations

SurModics has offices in Eden Prairie and Galway
Eden Prairie, US (HQ)
9924 W 74th St
Eden Prairie, US
9700 W 76th St #123
Galway, IE
IDA Business Park Ballinasloe, Co.
Show all (3)

SurModics Financials and Metrics

SurModics Revenue

SurModics's revenue was reported to be $100.08 m in FY, 2019
USD

Revenue (FY, 2019)

100.1m

Gross profit (FY, 2019)

86.4m

Gross profit margin (FY, 2019), %

86.4%

Net income (FY, 2019)

7.6m

EBIT (FY, 2019)

6.5m

Market capitalization (21-Jan-2020)

560.1m

Closing stock price (21-Jan-2020)

41.1

Cash (30-Sept-2019)

30.4m
SurModics's current market capitalization is $560.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

67.8m51.9m56.1m57.4m61.9m71.4m73.1m81.3m100.1m

Revenue growth, %

8%2%8%15%

Cost of goods sold

8.3m7.4m7.9m8.0m8.6m10.9m11.4m14.0m13.6m

Gross profit

59.5m44.5m48.2m49.4m53.3m60.5m61.7m67.3m86.4m
Annual
usdY, 2009Y, 2010FY, 2011Y, 2011FY, 2012Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

11.6m11.4m23.2m23.2m15.5m15.5m15.5m43.5m55.6m25.0m16.5m23.3m30.4m

Accounts Receivable

7.7m5.1m1.7b670.9b7.2m8.9m9.0m

Prepaid Expenses

1.2m2.5m3.9m

Inventories

4.2m3.5m3.3m2.8m3.0m3.6m3.5m4.0m4.5m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.5m)10.2m15.2m12.0m11.9b10.0m3.9m(4.5m)7.6m

Depreciation and Amortization

7.1m2.9m2.9m2.7m2.8m4.9m5.6m6.4m7.3m

Inventories

(1.1m)(343.0k)196.0k511.0k(162.0k)(143.0k)97.0k(513.0k)(543.0k)

Accounts Payable

1.9m(2.7m)518.0k905.0k368.0k5.2m(765.0k)
USDY, 2019

Revenue/Employee

296.1k

Financial Leverage

1.3 x
Show all financial metrics

SurModics Online and Social Media Presence

Embed Graph

SurModics News and Updates

Surmodics evaluating how FDA warning on paclitaxel-coated devices will affect trials of its own drug-coated balloon

Surmodics Inc said in a securities filing Monday that it was working with the Food and Drug Administration to clarify how the agency's Friday warning about paclitaxel-coated balloons and paclitaxel-eluting stents would affect the company's clinical trial evaluating SurVeil, its drug-coated balloon …

Informative Report on Medical Device Coatings Market 209 | Key Players like Surmodics, Inc., Covalon Technologies Ltd., Royal DSM, Hydromer. Inc., Precision Coatings Co. Inc., AST Products Inc.

Medical coatings range from lubrications to anti-microbial liquids to water repellent polymers, and each variety of coating is used on a multitude of devices for many different applications. Medical equipment is used at every phase of procedure, from basic check-ups, as well to surgeries and clinica…

Coatings for Medical Application Global Market 2017: Key Players – SurModics, Sono-Tek, Royal DSM, Hydromer, Biocoat

Wiseguyreports.Com Publish New Market Research Report On -“Coatings for Medical Application Global Market 2017: Key Players – SurModics, Sono-Tek, Royal DSM, Hydromer, Biocoat” Posted via Industry Today. Follow us on Twitter @IndustryToday

SurModics Blogs

Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 31, 2019-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 fourth quarter ended September 30, 2019 , and provided its

The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status

Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 29, 2019-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical

Surmodics to Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call on October 31

Surmodics to Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call on October 31 Content Import Fri, 10/25/2019 - 08:30 Surmodics to Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call on October 31 10/25/19 This release is a backfill from a New…

Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial

Study designed to evaluate safety, efficacy of the company’s next-generation SurVeil™ drug-coated balloon Company Raises 2019 Revenue and EPS Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 28, 2019-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic

Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 31, 2019-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 third quarter ended June 30, 2019 , and updated its financial

Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31

Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31 Content Import Tue, 07/23/2019 - 08:30 Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31 07/23/19 This release is a backfill from a News Wire …
Show more

SurModics Frequently Asked Questions

  • When was SurModics founded?

    SurModics was founded in 1979.

  • How many employees does SurModics have?

    SurModics has 369 employees.

  • What is SurModics revenue?

    Latest SurModics annual revenue is $100.1 m.

  • What is SurModics revenue per employee?

    Latest SurModics revenue per employee is $271.2 k.

  • Who are SurModics competitors?

    Competitors of SurModics include Varex Imaging, iScreen Vision and Bardy Diagnostics.

  • Where is SurModics headquarters?

    SurModics headquarters is located at 9924 W 74th St, Eden Prairie.

  • Where are SurModics offices?

    SurModics has offices in Eden Prairie and Galway.

  • How many offices does SurModics have?

    SurModics has 3 offices.